文章摘要
韩大莉,王庆久,邵艳梅,姜 涛,杜文杰.肺心通对慢性肺源性心脏病模型大鼠肺动脉高压、血流动力学及肺血管重构的影响[J].,2022,(11):2046-2050
肺心通对慢性肺源性心脏病模型大鼠肺动脉高压、血流动力学及肺血管重构的影响
Effect of Feixintong on Pulmonary Hypertension, Hemodynamics and Pulmonary Vascular Remodeling in Rats with Chronic Pulmonary Heart Disease
投稿时间:2021-10-09  修订日期:2021-10-31
DOI:10.13241/j.cnki.pmb.2022.11.008
中文关键词: 肺心通  慢性肺源性心脏病  肺动脉  血流动力学  肺血管重构
英文关键词: Feixintong  Chronic pulmonary heart disease  Pulmonary artery  Hemodynamics  Pulmonary vascular remodeling
基金项目:国家自然科学基金项目(81202761)
作者单位E-mail
韩大莉 潍坊医学院附属青岛医院(青岛市第八人民医院)呼吸与危重症医学科 山东 青岛 266100 baiyitianshi002@163.com 
王庆久 潍坊医学院附属青岛医院(青岛市第八人民医院)心内科 山东 青岛 266100  
邵艳梅 青岛大学附属医院呼吸与危重症医学科 山东 青岛 266000  
姜 涛 青岛大学附属医院急诊科 山东 青岛 266000  
杜文杰 青岛大学附属医院急诊科 山东 青岛 266000  
摘要点击次数: 615
全文下载次数: 349
中文摘要:
      摘要 目的:研究肺心通对慢性肺源性心脏病(CPHD)大鼠的治疗效果,并探讨其治疗对慢性肺源性心脏病大鼠肺动脉高压、血流动力学以及肺血管重构的影响。方法:30只Wistar大鼠被随机均分为正常对照组(Normal control)、模型组(Model)和肺心通组(Feixintong)。模型组和肺心通组大鼠腹腔注射野百合碱建立CPHD模型,肺心通组CPHD大鼠通过灌胃给药肺心通进行治疗3周。治疗3周后,测量三组大鼠0.3秒呼出量(FEV0.3)、呼出肺功能量(FVC)、肺动脉压、左室射血分数(Left ventricular ejection fraction,LVEF)、左心室舒张末期内径(Left ventricular end diastolic diameter ,LVEDD)、室间隔厚度 (Ventricular septal thickness,IVST)和左室后壁厚度(Left ventricular posterior wall thickness,LVPWT)、肺动脉收缩压(pulmonary artery systolic pressure,PASP)、血氧分压(Partial pressure of blood oxygen,PO2)、肺动脉平均压(mean pulmonary artery pressure,mPAP)以及舒张压(pulmonary artery diastolic pressure,PADP)以及肺血管重构相关指标。结果:与模型组大鼠相比,肺心通组大鼠活动量、饮食饮水量以及体重均显著增高,呼吸和舌色等症状均改善。肺心通治疗3周后,CPHD大鼠肺功能指标FEV0.3、FVC和FEV0.3/FVC均显著升高(P<0.05),心脏功能结构指标LVEF、LVEDD、IVST和LVPWT均显著升高(P<0.05),血流动力学指标PASP、PADP和mPAP均显著降低(P<0.05),以及肺血管重构指标MA、WT和WA均显著降低(P<0.05),而肺血管重构指标NMA却显著升高(P<0.05)。结论:肺心通对慢性肺源性心脏大鼠具有较好的治疗效果,可显著降低慢性肺源性心脏大鼠肺动脉高压,改善其血流动力学变化并有助于重构肺血管。
英文摘要:
      ABSTRACT Objective: To study the therapeutic effect of Feixintong on rats with chronic pulmonary heart disease (CPHD), and to explore the effects of its treatment on pulmonary hypertension, hemodynamics and pulmonary vascular remodeling in rats with chronic pulmonary heart disease. Methods: 30 Wistar rats were randomly divided into normal control group, model group and Feixintong group. Rats in the model group and Feixintong group were intraperitoneally injected with monocrotaline to establish a CPHD model. The CPHD rats in the Feixintong group were given Feixintong via intragastric administration for 3 weeks. After 3 weeks of treatment, the FEV0.3, FVC, LVEF, LVEDD, IVST, LVPWT, WBHSV, WBLSV, pv, HT and pulmonary vascular remodeling related indicators in the three groups of rats were measured. Results: Compared with the model group rats, the Feixintong group rats' activity, diet and water consumption and body weight were significantly increased, and symptoms such as breathing and tongue color were all improved. After 3 weeks of Feixintong treatment, the pulmonary function indexes FEV0.3, FVC and FEV0.3/FVC of CPHD rats increased significantly(P<0.05), and the cardiac function structural indexes LVEF, LVEDD, IVST and LVPWT all increased significantly(P<0.05), the hemodynamic indexesPASP, PADP and mPAP were all significantly reduced(P<0.05), and the pulmonary vascular remodeling indexes MA, WT and WA were all significantly reduced(P<0.05), while the pulmonary vascular remodeling index NMA was significantly increased(P<0.05). Conclusion: Feixintong has a good therapeutic effect on chronic pulmonary heart rats, which can significantly reduce pulmonary hypertension in chronic pulmonary heart rats, improve its hemodynamic changes and help rebuild pulmonary blood vessels.
查看全文   查看/发表评论  下载PDF阅读器
关闭